New weapon against advanced cancer begins human testing
NCT ID NCT06573294
Summary
This is the first-ever study in humans of an experimental antibody called GEN1057 for treating advanced solid tumors. The trial aims to find a safe dose and see early signs of whether the treatment can shrink tumors. It will enroll about 45 adults with metastatic or advanced cancers who have exhausted standard treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Universitari Vall d'Hebron
RECRUITINGBarcelona, Barcelona, 08035, Spain
-
National Cancer Center, Tsukiji 5-1-1
RECRUITINGTokyo, Japan
-
SCRI Oncology Partners
ACTIVE_NOT_RECRUITINGNashville, Tennessee, 37203, United States
-
South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
-
Start Madrid Centro Integral Oncologico Clara Campal CIOCC
RECRUITINGMadrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.